Already an admired senior poet to Virgil in the Eclogues , Varius by the mid-thirties, B.C. had established himself as the leading epic writer of his day . It is a sobering thought that we do not know even the titles of the serious hexameter works which had won him so high a reputation, except for de Morte, quoted four times by Macrobius.

Rudolf Pfeiffer believed that, as a young man, Callimachus wrote four books of Aetia. To these the poet added in his old age a Reply to his Critics , and a slightly revised version of his recent occasional elegy, the Lock of Berenice ; this revised Coma became the last poem in Aetia book 4, to be followed by an Epilogue which may mark a transition to the Iambi. Pfeiffer's theory generally held the field until the brilliant article of P. (...) J. Parsons, in ZPE 25 , 1–50. With the help of newly recovered papyrus fragments Parsons showed that a previously unplaced elegy celebrating a Nemean victory was connected to the story of Molorchus , who entertained Heracles before that hero killed the Nemean lion and instituted the Nemean Games; thus the poem belonged to Aetia book 3. Furthermore, various pieces of evidence converge to make it probable, if not wholly certain, that this substantial poem stood first in its book. So it appears that, at least in the final form of the Aetia, books 3–4 were framed by two poems honouring the wife of Ptolemy III Euergetes, namely Victoria Berenices and Coma Berenices. Soon afterwards a further important advance was made by E. Livrea , who perceived, on grounds of subject-matter as well as papyrology, that the poor man who sets a mousetrap in fr. 177 Pf. must be none other than Molorchus; note particularly the probable mention of Cleonae in fr. 177.37 Pf. = Supplementum Hellenisticum 259.37. Thus a new fragment of 38 lines accrued to the poem. These discoveries have some implications for the composition of the Aetia. Addition of a Coma Berenices to a pre-existent Aetia book 4 could be countenanced easily enough, but, as Parsons says , it would have required a much more radical, and therefore less plausible, revision for Callimachus to have added Victoria Berenices to a pre-existent Aetia book 3. Accordingly Parsons suggested that the original Aetia contained only books 1–2, united by the conversation with the Muses; then in his old age Callimachus compiled two more books, partly at least from poems already composed, and gave them a frame of two poems honouring Queen Berenice. Parsons' view has, I think, been widely accepted; Professor Lloyd-Jones wrote in SIFC 77 , 56 ‘No-one has yet argued against the simple modification of Pfeiffer's theory of the two editions of the Aetia which Mr. Parsons based on this discovery. The first edition comprised two books only.’. (shrink)

Nonnus, as well as being soaked in Homer and, no doubt, earlier epics on his particular theme , had a great affection for the Hellenistic master—above all Callimachus, Apollonius, Theocritus, and Euphorion. For this reason he can provide valuable help towards the study of fragments and new papyri. Pfeiffer, in his edition of the Callimachus fragments, is of course fully alive to this point, and regularly quotes Nonnus. From the other side there is a useful collection of parallels in Keydell's (...) Dtonysiaca and the new Nonnus lexicon will be invaluable, though not a complete substitute for actually reading the poem because imitation need not involve more than a small amount of verbal reminiscence. (shrink)

Michael Choniates (c. 1138–c. 1222), a pupil of Eustathius of Thessalonica, who was Greek Orthodox Metropolitan of Athens for some 25 years up to that city's capture by Frankish crusaders ina.d.1205, is best known to classical scholars as the possessor of probably the last complete copy of Callimachus'HecaleandAetia. He had brought with him from Constantinople many books of all kinds, and added to his collection when in Athens. Although an immense task, it would be well worth trying to identify all (...) Michael's classical allusions, as an indication of how much ancient Greek literature was still available just before Constantinople too succumbed to the crusaders. (shrink)

Acontius rhetorically addresses the young man to whom Cydippe's parents have betrothed her, whom he imagines as showing excessive familiarity while visiting the girl's sickbed. In line 146, ‘spes’ may be considered the vulgate reading; the noun can be used concretely, of the object of one's hopes , a person in whom hopes are centred , or sometimes as an endearment . For application to a girl with suitors, cf. Ovid, Met. 4.795 ‘multorumque fuit spes invidiosa procorum’. Or one could (...) take ‘spes’ in Her. 20.146 generally, = id quod spero. But, in any case, ‘spes’ is somewhat disappointing. After the strong imagery of 145 , we expect something no less definite in the pentameter, and, in particular, a word which will cohere with, and reinforce, the notion of providing access . In this respect ‘spes’ fails to contribute anything. Nor does the manuscript evidence point unambiguously to ‘spes’. Some manuscripts have the unmetrical ‘spem’, while Heinsius found in a Medicean manuscript the reading ‘sepem’, which was taken up by Burman, and by a number of other editors. To this, however, A. Palmer made an objection which seems not merely pedantic: ‘I should rather have expected per sepem; for a man has a right to go up to, as far as, another man's boundary.’. (shrink)

Both and are guaranteed by the London scholia , so the gap is reduced to the tantalizingly small one of a monosyllabic feminine noun in the accusative case, most probably of four letters. The number of possibilities cannot be unlimited. My own suggestion must necessarily remain in limbo in the present state of our knowledge concerning the poet or poets whom Callimachus is talking about, but at least it seems to me less bizarre than other restorations currently in the field.

Horace had good reason to know these lines since they come from the foundation oracle of one of his favourite places, Tarentum, delivered to the founder Phalanthus whom Horace mentions in Odes 2.6.11–12, ‘regnata petam Laconi | rura Phalantho’. It is a regular feature of such oracles that, however absurd and impossible they may seem, they will be fulfilled in a quite unexpected way.

As far as I am aware, it has generally been taken for granted that ‘Kato’ in the pentameter must be vocative. The double vocative ‘Visce’—‘Kato’ does not seem objectionable if ‘non’ were repeated as first word of the pentameter . None the less this is unexpected, and it seems at least worth considering the possibility that 'Kato’ might be nominative. The most plausible way of accounting for a nominative would be as subject of a relative clause. Further consequences would follow (...) almost inevitably: the word-ending doubtfully read. (shrink)

Some scholars have seen in ‘fulminat’ an allusion to Callimachus' βροντν οκ μν, λλ Διc , and that is reasonable enough, since Virgil contrasts the warlike fulminations of Octavian with mocking disparagement of his own very different lifestyle . But it may have escaped attention that Virgil seems to be imitating some lines by another Hellenistic poet, Rhianus ; the parallel has thought-provoking implications.

To ensure that the information resulting from research is relevant to patients, the Patient‐Centered Outcomes Research Institute eschews the “traditional health research” paradigm, in which investigators drive all aspects of research, in favor of one in which patients assume the role of research partner. If we accept the premise that patient engagement can offer fresh perspectives that shape research in valuable ways, then at least two important sets of questions present themselves. First, how are patients being engaged—and how should they (...) be engaged? Second, which patients are being engaged—and which patients should be? This set has received relatively less attention, and the neglect is surprising, given that the “who” question is conceptually prior to the question of “how.”This article focuses attention on the “who” of patient engagement in research. First, we provide background on the rationale for patient engagement, underscoring the importance of ensuring the representativeness of engaged patients. Second, we present what little is known about patients engaged in PCORI‐funded research. Third, we identify and discuss the ethical implications of ways in which current practices of patient identification and recruitment may lead to a lack of representativeness. These practices include reliance on the well‐connected and well‐informed, reliance on patients who are not well trained or well‐informed, and reliance on patient advocacy organizations. Finally, we consider several strategies for addressing these pitfalls in order to maximize the positive goals of patient engagement. Patient engagement is intended to address the inability of researchers, funders, and others to fully represent patient views and priorities, but without sufficient attention, the patients selected for this role may still leave important gaps. (shrink)

"_Minding Women _embraces a generation of scholarship, culminating in major new work by leading scholars who are reconfiguring feminist research. This important collection will again change the way we think about race, history, education, and the lives of girls." —_Sally Schwager_, Director Women's History Institute, Harvard University Research on women and girls has exploded during the past twenty years. Since 1977, when the _Harvard Educational Review_ published Carol Gilligan's now-classic article "In a Different Voice," in which she argued so persuasively (...) that women and girls must be understood on their own terms, researchers have been discovering, uncovering, and recovering women's ways of knowing, being, thinking, teaching, and learning. _Minding Women_ charts the wealth of thought and writing related to women and girls and education that this process of discovery has produced. _Minding Women_ begins with a "Classics" section—articles that call attention to the lack of research on girls and women and describe the effect this has had on knowledge and society. The contributors then discuss feminist pedagogy, and how it has changed and been refined over time. Girls and young women are the focus of the next section. Too often their voices and viewpoints are excluded from these discussions, so some of their own writings are included here. The book then explores women's educational history, showcasing some of the rich work in this area over the past twenty years. Identity issues are addressed in the final section, acknowledging that substantial differences exist among groups of women and girls on how they experience the world and their roles, prospects, and lives. (shrink)

Can academic scholarship harbor hope for humanity, or is it destined to become just another of many things that contribute to the demise of our species? Prodded by the unflinching observations of an eminent colleague, a journalist-turned-academic goes hunting for hope in the scholarship of her own field of mass media studies. Her search raises uncomfortable questions not only for herself, but for other academics who share her environmental concerns.

In this paper, we examine the case of psychedelic medicine for Alzheimer’s disease and related dementias (AD/ADRD). These “mind-altering” drugs are not currently offered as treatments to persons with AD/ADRD, though there is growing interest in their use to treat underlying causes and associated psychiatric symptoms. We present a research agenda for examining the ethics of psychedelic medicine and research involving persons living with AD/ADRD, and offer preliminary analyses of six ethical issues: the impact of psychedelics on autonomy and consent; (...) the impact of “ego dissolution” on persons experiencing a pathology of self; how psychedelics might impact caregiving; the potential exploitation of patient desperation; institutional review boards’ orientation to psychedelic research; and methods to mitigate inequity. These ethical issues are magnified for AD/ADRD but bear broader relevance to psychedelic medicine and research in other clinical populations. (shrink)

Participants in clinical research sometimes view participation as therapy or exaggerate potential benefits, especially in phase I or phase II trials. We conducted this study to discover what methods might improve cancer patients’ understanding of early-phase clinical trials. We randomly assigned 130 cancer patients from three U.S. medical centers who were considering enrollment in a phase I or phase II cancer trial to receive either a multimedia intervention or a National Cancer Institute pamphlet explaining the trial and its purpose. Intervention (...) participants were 32 times more likely to believe that the trial’s purpose was to examine safety and 60 % less likely to believe they would experience long-term benefit or cure. There was no difference in enrollment decision. However, while patients’ understanding of the trial’s purpose improved and expectations of long-term benefit diminished, half the respondents still believed they would experience long-term benefit or cure from participation. Therefore, we conclude that multimedia interventions such as this one may help oncologists to explain the risks and benefits of early-phase cancer trials in a way that patients can more easily understand, helping them to make more informed decisions about participation. But further research into other factors that influence patients’ beliefs about the outcome of enrollment is needed, both to modify the interventions and to determine how malleable patient beliefs are. (shrink)

This case explores the ethical landscape around recontacting a subject's relatives to return genetic research results when the informed consent form signed by the original cohort of subjects is silent on whether investigators may share new information with the research subject's family. As a result of rapid advances in genetic technology, methods to identify genetic markers can mature during the life course of a study. In this case, the investigators identified the genetic mutation responsible for the disorder after a number (...) of their original subjects had died. The researchers now have the ability to inform relatives of the subject about their risk of developing the same disease. Mark Rothstein, JD, from the University of Louisville School of Medicine, provides an overview of the medical/scientific, legal, and ethical issues underlying this case. Lauren Milner, PhD, and colleagues at Stanford University explore how the relationship between researcher and subject affect this debate. Seema Shah, JD, and colleagues at the National Institutes of Health and University of California, Los Angeles discuss whether and how requirements of the duty to warn are applicable in this case. (shrink)

This case looks at the question of how to consider obligations of confidentiality by a mental health professional who works for an institution and learns that a student has been using a drug intended for an animal research project. Dr. Paul Appelbaum, MD, a psychiatrist at Columbia University, examines the issue of the limits of confidentiality. Nicholas Steneck, PhD, a scholar in research misconduct at the University of Michigan, explores the obligations to report research misconduct. Walter Limehouse, MD, an ethicist (...) at the Medical University of South Carolina, considers the systems issues raised by this case and offers some suggestions that might change the institutional environment. (shrink)

The increasing complexity of human subjects research and its oversight has prompted researchers, as well as institutional review boards, to have a forum in which to discuss challenging or novel ethical issues not fully addressed by regulations. Research ethics consultation services provide such a forum. In this article, we rely on the experiences of a national Research Ethics Consultation Collaborative that collected more than 350 research ethics consultations in a repository and published 18 challenging cases with accompanying ethical commentaries to (...) highlight four contexts in which REC can be a valuable resource. REC assists: 1) investigators before and after the regulatory review; 2) investigators, IRBs, and other research administrators facing challenging and novel ethical issues; 3) IRBs and investigators with the increasing challenges of informed consent and risk/benefit analysis; and 4) in providing flexible and collaborative assistance to overcome study hurdles, mediate conflicts within a team, or directly engage with research participants. Institutions that have established, or plan to establish, REC services should work to raise the visibility of their service and engage in open communication with existing clinical ethics consult services as well as the IRB. While the IRB system remains the foundation for the ethical review of research, REC can be a valuable service for investigators, regulators, and research participants aligned with the goal of supporting ethical research. (shrink)